- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06464744
Efficacy of rTMS Treatment After Spinal Cord Injury
June 17, 2024 updated by: Mark Züchner, Oslo University Hospital
Investigating the Efficacy of rTMS Treatment in Improving Motor Function After Spinal Cord Injury: A Placebo-controlled Study
There is accumulating evidence that neuromodulation by repetitive transcranial magnetic stimulation (rTMS) of the motor cortex holds promise as a treatment for rehabilitation of motor function following a spinal cord injury.
This study is designed to assess the clinical potential of non-invasive stimulation of the primary motor cortex to improve motor functions.The results will help to evaluate the clinical relevance of motor cortex stimulation for motor functions in patients with spinal cord injury.
The outcomes of this study could potentially support the initiation of a larger clinical trial and the development of a new routine treatment.
Study Overview
Status
Recruiting
Conditions
Detailed Description
The investigators will recruit 20 patients with low cervical or thoracic ASIA C or D spinal cord injuries based on specific inclusion and exclusion criteria.
The patients will be randomized into 2 groups.
Each group will receive either the theta burst stimulation or the placebo stimulation.
rTMS will be delivered using a figure-of-eight coil positioned on the patient's head, targeting the leg area of the primary motor cortex.
After the motor threshold (MT) is determined patients will receive a unilateral 90% subthreshold theta burst stimulation for 3 minutes The protocol includes 15 stimulation sessions over a 3-week period.
The 12-week follow up consist of a series of electrophysiological and functional tests to assess upper and lower limb function bilaterally.
Secondary outcomes include pain using the NRS scale, and self-reported evaluation of autonomic functions before, during, and after the treatment.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mark Züchner, MD, PhD
- Phone Number: +47 23070000
- Email: mark.zuchner@medisin.uio.no
Study Locations
-
-
-
Oslo, Norway, 0372
- Recruiting
- Oslo University Hospital - Rikshospitalet
-
Contact:
- Mark Züchner, MD, PhD
- Phone Number: +4723070000
- Email: mark.zuchner@medisin.uio.no
-
Contact:
- Jean-Luc Boulland, Assoc. Prof.
- Phone Number: +4722851081
- Email: j.l.boulland@medisin.uio.no
-
Sub-Investigator:
- Jean-Luc Boulland, Assoc.Prof.
-
Sub-Investigator:
- Rozan Albanna, MD
-
Sub-Investigator:
- Akif Yucesoy, MD cand.
-
Sub-Investigator:
- Eis Annavini, MSc, PhD
-
Sub-Investigator:
- Lars Etholm, MD, PhD
-
Sub-Investigator:
- Sara Maria Allen, MCs
-
Sub-Investigator:
- Bjørn-Erik Juel, MSc, PhD
-
Principal Investigator:
- Mark Züchner, MD, PhD
-
Sub-Investigator:
- Ana Isabel Reinartz Groba, MSc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Age over 18 years and less than 80 years
- Chronic patients with an incomplete cervical and/or thoracic spinal cord injury (traumatic and non-traumatic) affecting upper and/or lower extremities (i.e., C4-T12 and classified as ASIA C or D) (Figure 138).
- Capable and willing to provide informed consent and able to adhere to the treatment schedule
- Patients who can be followed for the whole duration of the study
6.3 Exclusion criteria
Contraindication to rTMS:
- past severe head trauma
- history of epilepsy or ongoing epilepsy
- active cerebral tumor
- intracranial hypertension
- implanted ferromagnetic devices such as cardiac pacemaker and neurostimulator and cochlear implants
- pregnancy or lactation.
- Any clinically significant or unstable medical or psychiatric disorder
- Other ongoing research protocol or recent past protocol within two months before the inclusion
- History of treatment with Deep Brain Stimulation (DBS)
- Subjects protected by law (guardianship or tutelage measure)
- History of substance abuse (alcohol, drugs)
- Pending litigation
- Impossibility to understand the protocol or to fill out the forms
- Chronic use of sedative medication
- Participation in another clinical trial evaluating spinal cord injury
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo stimulation
Patients will receive stimulation from a placebo coil that only delivers skin tingling but no active brain stimulation.
|
The placebo coil looks identical to the active coil but it only delivers skin tingling and no active brain stimulation.
|
Active Comparator: Active stimulation
Patients will receive active brain stimulation from a magnetic figure-of-eight-coil.
|
Intermittent Theta burst stimulation will be delivered on the on the primary motor cortex using a figure-of-eight coil, supported by neuronavigation.
The stimulation intensity will be set to 90% of the motor threshold
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor evoked potentials
Time Frame: From enrollment to the end of follow up at 12 weeks
|
Motor evoked potentials will be recorded at the start and the end of each stimulation session.
|
From enrollment to the end of follow up at 12 weeks
|
Global spasticity
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
Spasticity will be evaluated by using the modified Ashworth scale from 0 (no spasticity) to 4 (rigid extremities).
|
From enrollment to the end of follow-up at 12 weeks
|
Spasticity lower extremities
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
The Wartenberg pendulum is an objective test to assess the biomechanical properties of spasticity.The test consists of dropping the leg of a relaxed patient from a horizontal position and measuring oscillatory movements with a goniometer.
|
From enrollment to the end of follow-up at 12 weeks
|
Nine-Hole Peg Test
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
The Nine-Hole Peg Test is used to measure manual dexterity in patients with various neurological diagnoses.
It is described in the literature to explore upper extremity function.
Patients are asked to take nine pegs (7 mm diameter, 32 mm length) from a container (square box measuring 100 x 100 x 10 mm), one by one, and place them into the holes on the board, as quickly as possible.
Scores are based on the time taken to complete the test activity, recorded in seconds.
|
From enrollment to the end of follow-up at 12 weeks
|
10-meter walking test
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
The 10-meter walk test (10MWT) is used to assess walking capabilities and walking speed in patients with gait impairments.
Three trials will be recorded at the patient's fastest walking speed.
The three trials are averaged and the gait speeds are documented in meters/second.
|
From enrollment to the end of follow-up at 12 weeks
|
Lower extremities kinematics
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
Movement kinematics will be extracted from recordings with 3D motion capture trackers that will record joint coordinates in time.
|
From enrollment to the end of follow-up at 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Numeric scale rating for pain evaluation
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
The analgesic efficacy of the stimulation protocol will be measured by the numeric scale rating (NRS), a self-reported measure in which patients rate their pain on a scale from 0 (no pain) to 10 (worst pain).
|
From enrollment to the end of follow-up at 12 weeks
|
European myelopathy score
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
The European myelopathy score is a reliable tool to assess functional recovery.
The score ranges from 5 to 18. Higher values indicate better neurological function (outcome).
|
From enrollment to the end of follow-up at 12 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Potential adverse effect
Time Frame: From enrollment to the end of follow-up at 12 weeks
|
In general, rTMS is a safe method. The use of exclusion criteria and ear plugs during stimulation will reduce side effects. Potential risks or side effects of rTMS include:
|
From enrollment to the end of follow-up at 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Bjørn Atle Bjørnbeth, MD,PhD, Oslo University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 15, 2024
Primary Completion (Estimated)
September 1, 2028
Study Completion (Estimated)
September 1, 2029
Study Registration Dates
First Submitted
June 5, 2024
First Submitted That Met QC Criteria
June 17, 2024
First Posted (Actual)
June 18, 2024
Study Record Updates
Last Update Posted (Actual)
June 18, 2024
Last Update Submitted That Met QC Criteria
June 17, 2024
Last Verified
June 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 635283
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Spinal Cord Injuries
-
Khon Kaen UniversityUnknownInjuries, Spinal Cord
-
Universidade do Vale do ParaíbaCompletedInjuries, Spinal Cord
-
InVivo TherapeuticsTerminated
-
Ekso BionicsBurke Medical Research InstituteCompletedInjuries, Spinal CordUnited States
-
ReWalk Robotics, Inc.Unknown
-
Shepherd Center, Atlanta GACompletedInjuries, Spinal Cord
-
Wroclaw Medical UniversityInstitute of Immunology and Experimental Therapy of the Polish Academy of... and other collaboratorsUnknownComplete Spinal Cord InjuriesPoland
-
M.D. Anderson Cancer CenterActive, not recruitingMetastatic Epidural Spinal Cord CompressionUnited States
Clinical Trials on Placebo stimulation using a placebo coil
-
Sheba Medical CenterCompleted
-
All India Institute of Medical Sciences, New DelhiNot yet recruiting
-
University of RegensburgCompleted
-
University Hospital, CaenCompletedAuditory Hallucinations in Patients With Schizophrenic DisordersFrance
-
Third Affiliated Hospital, Sun Yat-Sen UniversityNot yet recruitingMultiple Sclerosis | Depression, Anxiety
-
Rupert LanzenbergerUnknown
-
Centre for Addiction and Mental HealthRecruitingAutism Spectrum Disorder | Major Depressive DisorderCanada
-
Mclean HospitalTerminatedAnxiety | Major Depressive DisorderUnited States
-
Technical University of MunichGerman Research FoundationCompleted